What have we learnt from the past – would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?

BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors with a broad range of local and systemic treatment options. Still a lack of data regarding treatment sequences exists. The aim of this study was to analyse outcomes in GEP-NETs depending on stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Stiefel, Rahel, Lehmann, Kuno, Winder, Thomas, Siebenhüner, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926660/
https://www.ncbi.nlm.nih.gov/pubmed/36782152
http://dx.doi.org/10.1186/s12885-023-10567-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926660/
https://www.ncbi.nlm.nih.gov/pubmed/36782152
http://dx.doi.org/10.1186/s12885-023-10567-1

Ejemplares similares